TY - JOUR
T1 - A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman
T2 - Oman Lupus Study
AU - Al-Adhoubi, Nasra K.
AU - Al-Balushi, Farida
AU - Al Salmi, Issa
AU - Ali, Maha
AU - Al Lawati, Talal
AU - Al Lawati, Batool S.H.
AU - Abdwani, Reem
AU - Al Shamsi, Ali
AU - Al Kaabi, Juma
AU - Al Mashaani, Musallam
AU - Krishna Jha, Divij
AU - Sayed, Sherin
AU - Al-Araimi, Tariq
AU - Liyanage, Prabha
AU - Al Shirawi, Ali
AU - Al Wahshi, Humaid A.
N1 - Publisher Copyright:
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Aim: This study is a longitudinal multicenter study which aims to find the prevalence, the demographic data, survival and mortality rates of patients with systemic lupus erythematosus (SLE) in Oman. Method: All Omani patients, pediatrics and adults diagnosed with SLE, who fulfill either the 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics classifications criteria for SLE were included from January 2006 till February 2020. Results: In total 1160 patients were included in this cohort. Data analysis showed that patient’s ages ranged from 2-82 years with female predominance and female-to-male ratio of 7:1 (87.7% female,12.3% male). The mean prevalence of SLE among different age groups was 38.8 (range 5-63 per 100 000 inhabitants). The mortality rate was found to be 5%. Male patients had significantly higher mortality rate than females (7.6% vs 5.4%, P value =.04). Sepsis was the commonest cause of mortality (34%). The coexistence of systemic sclerosis correlates significantly with death (P =.002). Survival analysis in our data showed 5, 10, 20, 40-year survival rates of 100%, 100%, 99% and 90% respectively for antinuclear antibody (ANA) positive patients and lower survival rate for ANA negative patients with 5,10, 20, 40-year survival rates of 100, 99%, 99% and 75%, respectively. Conclusion: This study showed that the mean prevalence of SLE in Oman to be 38.8 (range 5-63) per 100 000 inhabitants. The 40-year survival rate among patients with positive ANA was found to be 90%, while patients with negative ANA had worse survival outcomes.
AB - Aim: This study is a longitudinal multicenter study which aims to find the prevalence, the demographic data, survival and mortality rates of patients with systemic lupus erythematosus (SLE) in Oman. Method: All Omani patients, pediatrics and adults diagnosed with SLE, who fulfill either the 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics classifications criteria for SLE were included from January 2006 till February 2020. Results: In total 1160 patients were included in this cohort. Data analysis showed that patient’s ages ranged from 2-82 years with female predominance and female-to-male ratio of 7:1 (87.7% female,12.3% male). The mean prevalence of SLE among different age groups was 38.8 (range 5-63 per 100 000 inhabitants). The mortality rate was found to be 5%. Male patients had significantly higher mortality rate than females (7.6% vs 5.4%, P value =.04). Sepsis was the commonest cause of mortality (34%). The coexistence of systemic sclerosis correlates significantly with death (P =.002). Survival analysis in our data showed 5, 10, 20, 40-year survival rates of 100%, 100%, 99% and 90% respectively for antinuclear antibody (ANA) positive patients and lower survival rate for ANA negative patients with 5,10, 20, 40-year survival rates of 100, 99%, 99% and 75%, respectively. Conclusion: This study showed that the mean prevalence of SLE in Oman to be 38.8 (range 5-63) per 100 000 inhabitants. The 40-year survival rate among patients with positive ANA was found to be 90%, while patients with negative ANA had worse survival outcomes.
KW - clinical aspects
KW - epidemiology
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85107157880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107157880&partnerID=8YFLogxK
U2 - 10.1111/1756-185X.14130
DO - 10.1111/1756-185X.14130
M3 - Article
C2 - 34058079
AN - SCOPUS:85107157880
SN - 1756-1841
VL - 24
SP - 847
EP - 854
JO - International Journal of Rheumatic Diseases
JF - International Journal of Rheumatic Diseases
IS - 6
ER -